<!DOCTYPE html>
<html lang="en-us">

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
    
    
    
  
  

  

  
  
  
    
  
  <meta name="description" content="Two hydroxypyridinone-containing actinide decorporation agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), are being developed for the treatment of internal actinide contamination by chelation therapy. Dose-response efficacy profiles in mice were established for the removal of intravenously injected (238)Pu and (241)Am after parenteral and oral treatment with these chelators. In both cases, presumed efficacious doses promoted substantially greater actinide elimination rates than the currently approved agent, diethylenetriamine-pentaacetic acid, considering two different interspecies scaling methods for the conversion of human doses to equivalent rodent dose levels. In addition, genotoxicity of both ligands was assessed using the Salmonella/ Escherichia coli /microsome plate incorporation test and the Chinese hamster ovary cell chromosome aberration assay, showing that neither ligand is genotoxic, in the presence and absence of metabolic activation. Finally, maximum tolerated dose studies were performed in rats for seven consecutive daily oral administrations with the chelators, confirming the safety of the presumed efficacious doses for 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). The results of these studies add to the growing body of evidence that both decorporation agents have remarkable decorporation efficacy properties and promising safety toxicology profiles. These results are necessary components of the regulatory approval process and will help determine the optimal human dosing regimens for the treatment of internal radionuclide contamination.">

  
  <link rel="alternate" hreflang="en-us" href="/publication/bunin-dose-dependent-2013/">

  


  
  
  
  <meta name="theme-color" content="#6baed6">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.css" integrity="sha256-SHMGCYmST46SoyGgo4YR/9AlK1vf3ff84Aq9yK4hdqM=" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono%7CMuli:400,700%7CRaleway%7CAnton%7CComfortaa:700%7CCatamaran:700&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  




  


  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/publication/bunin-dose-dependent-2013/">

  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="HOPO Therapeutics">
  <meta property="og:url" content="/publication/bunin-dose-dependent-2013/">
  <meta property="og:title" content="Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen. | HOPO Therapeutics">
  <meta property="og:description" content="Two hydroxypyridinone-containing actinide decorporation agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), are being developed for the treatment of internal actinide contamination by chelation therapy. Dose-response efficacy profiles in mice were established for the removal of intravenously injected (238)Pu and (241)Am after parenteral and oral treatment with these chelators. In both cases, presumed efficacious doses promoted substantially greater actinide elimination rates than the currently approved agent, diethylenetriamine-pentaacetic acid, considering two different interspecies scaling methods for the conversion of human doses to equivalent rodent dose levels. In addition, genotoxicity of both ligands was assessed using the Salmonella/ Escherichia coli /microsome plate incorporation test and the Chinese hamster ovary cell chromosome aberration assay, showing that neither ligand is genotoxic, in the presence and absence of metabolic activation. Finally, maximum tolerated dose studies were performed in rats for seven consecutive daily oral administrations with the chelators, confirming the safety of the presumed efficacious doses for 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). The results of these studies add to the growing body of evidence that both decorporation agents have remarkable decorporation efficacy properties and promising safety toxicology profiles. These results are necessary components of the regulatory approval process and will help determine the optimal human dosing regimens for the treatment of internal radionuclide contamination."><meta property="og:image" content="img/map[gravatar:%!s(bool=false) shape:square]">
  <meta property="twitter:image" content="img/map[gravatar:%!s(bool=false) shape:square]"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2020-04-05T05:18:33&#43;00:00">
    
    <meta property="article:modified_time" content="2013-01-01T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "/publication/bunin-dose-dependent-2013/"
  },
  "headline": "Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen.",
  
  "datePublished": "2020-04-05T05:18:33Z",
  "dateModified": "2013-01-01T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Deborah I Bunin"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "HOPO Therapeutics",
    "logo": {
      "@type": "ImageObject",
      "url": "/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_192x192_fill_lanczos_center_2.png"
    }
  },
  "description": "Two hydroxypyridinone-containing actinide decorporation agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), are being developed for the treatment of internal actinide contamination by chelation therapy. Dose-response efficacy profiles in mice were established for the removal of intravenously injected (238)Pu and (241)Am after parenteral and oral treatment with these chelators. In both cases, presumed efficacious doses promoted substantially greater actinide elimination rates than the currently approved agent, diethylenetriamine-pentaacetic acid, considering two different interspecies scaling methods for the conversion of human doses to equivalent rodent dose levels. In addition, genotoxicity of both ligands was assessed using the Salmonella/ Escherichia coli /microsome plate incorporation test and the Chinese hamster ovary cell chromosome aberration assay, showing that neither ligand is genotoxic, in the presence and absence of metabolic activation. Finally, maximum tolerated dose studies were performed in rats for seven consecutive daily oral administrations with the chelators, confirming the safety of the presumed efficacious doses for 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). The results of these studies add to the growing body of evidence that both decorporation agents have remarkable decorporation efficacy properties and promising safety toxicology profiles. These results are necessary components of the regulatory approval process and will help determine the optimal human dosing regimens for the treatment of internal radionuclide contamination."
}
</script>

  

  


  


  





  <title>Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen. | HOPO Therapeutics</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">HOPO Therapeutics</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">HOPO Therapeutics</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/#"><span>Home</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#posts"><span>News</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/science/"><span>Science</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/about/"><span>About</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      

      

      

    </ul>

  </div>
</nav>


  <div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen.</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span>Deborah I Bunin</span>, <span>Polly Y Chang</span>, <span>Rupa S Doppalapudi</span>, <span>Edward S Riccio</span>, <span>Dahlia An</span>, <span>Erin E Jarvis</span>, <span>Birgitta Kullgren</span>, <span>Rebecca J Abergel</span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    January 2013
  </span>
  

  

  

  
  
  

  
  

</div>

    











  



<div class="btn-links mb-3">
  
  








  
    
  



<a class="btn btn-outline-primary my-1 mr-1" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3633606&amp;tool=pmcentrez&amp;rendertype=abstract" target="_blank" rel="noopener">
  PDF
</a>



<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/bunin-dose-dependent-2013/cite.bib">
  Cite
</button>













<a class="btn btn-outline-primary my-1 mr-1" href="https://doi.org/10.1667/RR3115.1" target="_blank" rel="noopener">
  DOI
</a>



</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">Two hydroxypyridinone-containing actinide decorporation agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), are being developed for the treatment of internal actinide contamination by chelation therapy. Dose-response efficacy profiles in mice were established for the removal of intravenously injected (238)Pu and (241)Am after parenteral and oral treatment with these chelators. In both cases, presumed efficacious doses promoted substantially greater actinide elimination rates than the currently approved agent, diethylenetriamine-pentaacetic acid, considering two different interspecies scaling methods for the conversion of human doses to equivalent rodent dose levels. In addition, genotoxicity of both ligands was assessed using the Salmonella/ Escherichia coli /microsome plate incorporation test and the Chinese hamster ovary cell chromosome aberration assay, showing that neither ligand is genotoxic, in the presence and absence of metabolic activation. Finally, maximum tolerated dose studies were performed in rats for seven consecutive daily oral administrations with the chelators, confirming the safety of the presumed efficacious doses for 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). The results of these studies add to the growing body of evidence that both decorporation agents have remarkable decorporation efficacy properties and promising safety toxicology profiles. These results are necessary components of the regulatory approval process and will help determine the optimal human dosing regimens for the treatment of internal radionuclide contamination.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>Radiation research</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    



<div class="article-tags">
  
  <a class="badge badge-light" href="/tags/mutation/">Mutation</a>
  
  <a class="badge badge-light" href="/tags/humans/">Humans</a>
  
  <a class="badge badge-light" href="/tags/animals/">Animals</a>
  
  <a class="badge badge-light" href="/tags/signal-transduction/">Signal Transduction</a>
  
  <a class="badge badge-light" href="/tags/chelating-agents/">Chelating Agents</a>
  
  <a class="badge badge-light" href="/tags/chelating-agents-chemistry/">Chelating Agents: chemistry</a>
  
  <a class="badge badge-light" href="/tags/mice/">Mice</a>
  
  <a class="badge badge-light" href="/tags/female/">Female</a>
  
  <a class="badge badge-light" href="/tags/male/">Male</a>
  
  <a class="badge badge-light" href="/tags/rats/">Rats</a>
  
  <a class="badge badge-light" href="/tags/safety/">Safety</a>
  
  <a class="badge badge-light" href="/tags/chelating-agents-administration-dosage/">Chelating Agents: administration &amp; dosage</a>
  
  <a class="badge badge-light" href="/tags/americium/">Americium</a>
  
  <a class="badge badge-light" href="/tags/plutonium/">Plutonium</a>
  
  <a class="badge badge-light" href="/tags/americium-chemistry/">Americium: chemistry</a>
  
  <a class="badge badge-light" href="/tags/bystander-effect/">Bystander Effect</a>
  
  <a class="badge badge-light" href="/tags/bystander-effect-drug-effects/">Bystander Effect: drug effects</a>
  
  <a class="badge badge-light" href="/tags/chelating-agents-adverse-effects/">Chelating Agents: adverse effects</a>
  
  <a class="badge badge-light" href="/tags/chelating-agents-pharmacology/">Chelating Agents: pharmacology</a>
  
  <a class="badge badge-light" href="/tags/cho-cells/">CHO Cells</a>
  
  <a class="badge badge-light" href="/tags/cricetinae/">Cricetinae</a>
  
  <a class="badge badge-light" href="/tags/cricetulus/">Cricetulus</a>
  
  <a class="badge badge-light" href="/tags/dose-response-relationship/">Dose-Response Relationship</a>
  
  <a class="badge badge-light" href="/tags/drug/">Drug</a>
  
  <a class="badge badge-light" href="/tags/maximum-tolerated-dose/">Maximum Tolerated Dose</a>
  
  <a class="badge badge-light" href="/tags/mutagenicity-tests/">Mutagenicity Tests</a>
  
  <a class="badge badge-light" href="/tags/plutonium-chemistry/">Plutonium: chemistry</a>
  
  <a class="badge badge-light" href="/tags/pyridones/">Pyridones</a>
  
  <a class="badge badge-light" href="/tags/pyridones-administration-dosage/">Pyridones: administration &amp; dosage</a>
  
  <a class="badge badge-light" href="/tags/pyridones-adverse-effects/">Pyridones: adverse effects</a>
  
  <a class="badge badge-light" href="/tags/pyridones-chemistry/">Pyridones: chemistry</a>
  
  <a class="badge badge-light" href="/tags/pyridones-pharmacology/">Pyridones: pharmacology</a>
  
  <a class="badge badge-light" href="/tags/signal-transduction-drug-effects/">Signal Transduction: drug effects</a>
  
  <a class="badge badge-light" href="/tags/toxicity-tests/">Toxicity Tests</a>
  
  <a class="badge badge-light" href="/tags/tumor-suppressor-protein-p53/">Tumor Suppressor Protein p53</a>
  
  <a class="badge badge-light" href="/tags/tumor-suppressor-protein-p53-genetics/">Tumor Suppressor Protein p53: genetics</a>
  
</div>



<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=/publication/bunin-dose-dependent-2013/&amp;text=Dose-dependent%20efficacy%20and%20safety%20toxicology%20of%20hydroxypyridinonate%20actinide%20decorporation%20agents%20in%20rodents:%20towards%20a%20safe%20and%20effective%20human%20dosing%20regimen." target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=/publication/bunin-dose-dependent-2013/&amp;t=Dose-dependent%20efficacy%20and%20safety%20toxicology%20of%20hydroxypyridinonate%20actinide%20decorporation%20agents%20in%20rodents:%20towards%20a%20safe%20and%20effective%20human%20dosing%20regimen." target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=Dose-dependent%20efficacy%20and%20safety%20toxicology%20of%20hydroxypyridinonate%20actinide%20decorporation%20agents%20in%20rodents:%20towards%20a%20safe%20and%20effective%20human%20dosing%20regimen.&amp;body=/publication/bunin-dose-dependent-2013/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=/publication/bunin-dose-dependent-2013/&amp;title=Dose-dependent%20efficacy%20and%20safety%20toxicology%20of%20hydroxypyridinonate%20actinide%20decorporation%20agents%20in%20rodents:%20towards%20a%20safe%20and%20effective%20human%20dosing%20regimen." target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://web.whatsapp.com/send?text=Dose-dependent%20efficacy%20and%20safety%20toxicology%20of%20hydroxypyridinonate%20actinide%20decorporation%20agents%20in%20rodents:%20towards%20a%20safe%20and%20effective%20human%20dosing%20regimen.%20/publication/bunin-dose-dependent-2013/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=/publication/bunin-dose-dependent-2013/&amp;title=Dose-dependent%20efficacy%20and%20safety%20toxicology%20of%20hydroxypyridinonate%20actinide%20decorporation%20agents%20in%20rodents:%20towards%20a%20safe%20and%20effective%20human%20dosing%20regimen." target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>












  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/deborah-i-bunin/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/polly-y-chang/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/rupa-s-doppalapudi/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/edward-s-riccio/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/dahlia-an/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/erin-e-jarvis/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/birgitta-kullgren/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/rebecca-j-abergel/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  










  
  



  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.js" integrity="sha256-EErZamuLefUnbMBQbsEqu1USa+btR2oIlCpBJbyD4/g=" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = false;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    

    
    

    

    
    

    
    

    
    

    
    
    
    
    
    
    
    
    
    
    
    
    <script src="/js/academic.min.6f7ce8be710290b8c431bbc97f405d15.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/privacy/">Privacy Policy</a>
    
    
       &middot; 
      <a href="/terms/">Terms & Conditions</a>
    
  </p>
  

  <p class="powered-by">
    © 2020 HOPO Therapeutics, Inc. &middot; All Rights Reserved 

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
